Merck Sharp & Dohme Corporation

Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Other

Southern Research Institute

Msd R&d (china) Co., Ltd.

Schering Corportion

Joseph A Kozlowski

Wensheng Yu

Neng-Yang Shih

Stuart B Rosenblum

Ling Tong

Bandarpalle B Shankar

Brian J Lavey

F George Njoroge

Dansu Li

Jian Liu

Vinay M Girijavallabhan

M Arshad Siddiqui

Janeta Popovici-Muller

Brian F McGuinness

Stuart W McCombie

Kevin X Chen

Zhuyan Guo

Wei K Chang

Douglas Walsh Hobbs

Joel G Berger

Srikanth Venkatraman

Sundeep Dugar

John W Clader

Xianhai Huang

Wing C Tom

Peter Orth

Samuel Chackalamannil

Yongxin Han

Hao Wu

Michael J Green

Craig Alan Coburn

David James Witter

Vincent Stewart Madison

Wayne D Vaccaro

Shuwen He

Christopher W Boyce

Phieng Siliphaivanh

Liangqin Guo

Margaret H Sherlock

Zhaoning Zhu

Bin Hu

Kevin J Wilson

Younong Yu

Brian Alexander McKittrick

Frank W Bennett

Kun Liu

Jongwon Lim

Hongjun Zhang

David L Sloman

Guoqing Li

Milana M Maletic

Ronald L Wolin

Ronald M Kim

Robert D Mazzola, Jr

Tin-Yau Chan

Alexander Pasternak

Michael P Dwyer

Michael W Miller

Joseph Michael Kelly

Craig D Boyle

Purakkattle J Biju

Patrick A Pinto

Raman Kumar Bakshi

Li Xiao

Brian M Andresen

Wei Liu

John J Baldwin

William J Greenlee

Andrew William Stamford

Lihu Yang

Ravi P Nargund

Yimin Qian

Robert G Aslanian

Michael D Altman

Lei Chen

Ashok Arasappan

Kevin D McCormick

John A Secrist, Iii

Michael Berlin

Xing Dai

Gerald Wayne Shipps, Jr

Joey Lee Methot

Pauline C Ting

Malcolm Maccoss

Hua Zhou

Philippe G Nantermet

Ping Liu

David Brian Olsen

Fei Sun

Duane E DeMong

Sunil Paliwal

Deen Tulshian

Daniel M Solomon

Zhi-Cai Shi

Eric J Gilbert

Subramaniam Ananthan

Ying-Duo Gao

Richard Soll

Nunzio Sciammetta

Jianmin Fu

The present invention relates to Compounds of Formula I and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, R, X and A are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing HIV infection in a subject.

Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection

The present invention discloses oxazolidinone compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A and E, are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Oxazolidinone compounds and methods of use thereof as antibacterial agents

The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, R, R, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing cancer, inflammation, neurodegeneration disease and/or diabetes in a subject.

Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor

Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject. 

Hepatitis C virus inhibitors

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

Compounds that are ERK inhibitors

The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', RR, Rand Rare as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases

Growing community of inventors

Summit, NJ, United States of America

Joseph A Kozlowski